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Background: Nodular ground-glass opacities (nGGO) are a specific type of lung adenocarcinoma. ALK rearrangements
and driver mutations such as EGFR and K-ras are frequently found in all types of lung adenocarcinoma. EGFR mutations
play a role in the early carcinogenesis of nGGOs, but the role of ALK rearrangement remains unknown.
Methods: We studied 217 nGGOs resected from 215 lung cancer patients. Pathology, tumor size, tumor disappearance
rate, and the EGFR and ALK markers were analyzed.
Results: All but one of the resected nGGOs were adenocarcinomas. ALK rearrangements and EGFR mutations were
found in 6 (2.8%) and 119 (54.8%) cases. The frequency of ALK rearrangement in nGGO was significantly lower than
previously reported in adenocarcinoma. Advanced disease stage (p = 0.018) and larger tumor size (p = 0.037) were
more frequent in the ALK rearrangement-positive group than in ALK rearrangement-negative patients. nGGOs with
ALK rearrangements were associated with significantly higher pathologic stage and larger maximal and solid diameter
in comparison to EGFR-mutated lesions.
Conclusion: ALK rearrangement is rare in lung cancer with nGGOs, but is associated with advanced stage and larger
tumor size, suggesting its association with aggressive progression of lung adenocarcinoma. ALK rearrangement may
not be important in early pathogenesis of nGGO.
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Low-dose chest computed tomography (CT) for lung
cancer screening has increased the detection of solitary
pulmonary nodules (SPN) not visualized on chest radi-
ography, and has contributed to a reduction in lung can-
cer mortality [1]. Some of these visualized nodules are
nodular ground-glass opacities (nGGOs). nGGOs on
chest CT are defined as hazy, increased attenuation of
the lung with preservation of bronchial and vascular
margins, and are classified as pure and mixed GGOs,
which contain a solid component [2].* Correspondence: ctlee@snu.ac.kr
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unless otherwise stated.Nodular GGOs can be found in eosinophilic lung dis-
ease, pulmonary lymphoproliferative disorder, and inter-
stitial fibrosis, with a persistent nGGO being a possible
sign of early lung cancer [3]. The natural development
of nGGO follows a stepwise progression from atypical
adenomatous hyperplasia (AAH) to adenocarcinoma
in situ (AIS: formerly bronchioloadenocarcinoma), to
microinvasive adenocarcinoma (MIA), and finally to in-
vasive adenocarcinoma (IA) [4]. However, some adeno-
carcinomas do not follow this pathway, manifesting as
consolidation and/or solid mass, with different genetic
profiles. Therefore, lung adenocarcinoma exhibits het-
erogeneity in pathogenesis and progression [5].
Several driver mutations have been identified in lung
cancer, such as epidermal growth factor receptor (EGFR)
and K-ras mutations and anaplastic lymphoma kinaseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mutations respond well to the EGFR tyrosine kinase
inhibitors [6-8]. The fusion of echinoderm microtubule-
associated protein-like 4 (EML4) and ALK gene by re-
arrangement in non-small cell lung cancer was identified
[9] and developed as a target of the ALK tyrosine kinase
inhibitor, crizotinib [10,11]. These biomarkers predict re-
sponse to these molecular targeting agents and testing
for these markers is recommended in lung cancer
patients [12,13], enabling personalized medicine for pa-
tients harboring EGFR mutations or ALK gene rearrange-
ments. It is therefore very important to investigate the
frequencies and clinical implications of these driver muta-
tions in nGGOs, a specific type of lung adenocarcinoma.
Many studies have reported that EGFR mutations are
frequent in lung cancer with nGGOs, even in precancer-
ous lesions such as AAH [14-17]; however, the role of
ALK rearrangement in nGGOs remains unknown. We
analyzed patients with lung cancer with nodular GGOs
to investigate the correlation between biomarker status
and clinicopathological and radiologic characteristics
and to determine the roles of ALK rearrangements and
EGFR mutations in nGGOs.
Methods
Patients
Among the patients who underwent surgical resection of
their CT-identified nGGOs between August 2008 and
March 2013 at Seoul National University Bundang Hospital
(SNUBH), we selected patients who were diagnosed with
lung cancer by pathologic confirmation of the surgical spe-
cimen. Multiple nGGOs in a single patient were considered
different cases of nGGO. Patient data were extracted from
medical records, including those pertaining to the age at
the time of surgery, sex, smoking history quantified by
packs per year, tumor histology, pathologic tumor stage,
and biomarker status. This study was approved and
individual patient consent waived by the institutional
review board of Seoul National University Bundang
Hospital (B-1305-202-102).
Radiologic evaluation
Chest CT scans were performed preoperatively in each
patient. All CT images were reviewed with a pulmon-
ary window setting (window width, 2000 HU; window
level, −500 HU) and mediastinal window setting (window
width 440 HU, window level 45 HU). GGOs appear in
pulmonary window images of chest CT, but disappear on
mediastinal window images [3]. We included all nodules
that contained any amount of GGO.
To evaluate the proportion of the solid component
in the nGGOs, we measured the maximum transverse
diameter (Tmax) and maximum perpendicular diameter
(Pmax) of both the pulmonary and mediastinal windowsettings (pTmax, mTmax, pPmax, mPmax) and calculated
the tumor shadow disappearance rate (TDR) in all
nGGOs. TDR was calculated using the following formula:
TDR = 1 − (mTmax ×mPmax /pTmax × pPmax) [18].
Histopathology review
Surgical specimens were reviewed by an experienced path-
ologist (J-H Chung) and another pathologist (H Kim).
TNM classification was performed according to the Union
for International Cancer Control and the American Joint
Committee on Cancer staging system, 7th edition [19].
In some participants, lymph node dissection was not
performed because lymphatic invasion was deemed un-
likely in the preoperative evaluation; these participants
were considered N0 stage. Lung cancer was histologi-
cally classified as adenocarcinoma or squamous cell car-
cinoma. The majority of participants were diagnosed
with adenocarcinoma and were categorized according
to the 2011 International Association for the Study of
Lung Cancer/American Thoracic Society/European Re-
spiratory Society (IASLC/ATS/ERS) classification sys-
tem as adenocarcinoma in situ (AIS), minimally invasive
adenocarcinoma (MIA), and various types of invasive
adenocarcinoma (IA) [4].
Molecular analysis
We analyzed the samples for EGFR mutation and ALK
rearrangements. Genomic DNA was extracted from
formalin-fixed paraffin-embedded specimens. Exons 18–
21 of the EGFR gene were analyzed by PCR amplifica-
tion and sequencing with an ABI Prism 3100 DNA
analyzer and standard protocols. Peptide nucleic acid
(PNA)-mediated PCR clamping or pyrosequencing
methods are more sensitive than direct sequencing (DS)
for EGFR mutation detection [20], but we have found
that all of these methods are appropriate when sufficient
tumor cells are properly micro-dissected and analyzed
within a meticulously controlled turnaround time at a
single institute (SNUBH) [21]. We included only nGGO
specimens resected en bloc to ensure sufficient tumor
cell sampling; this is the main strength of this study, as
it provided highly accurate DS detection of EGFR
mutations.
To detect ALK rearrangements, we first screened the
tissues by immunohistochemistry (IHC) with monoclo-
nal anti-ALK antibody (clone 5A4, Novocastra, 1:30,
Newcastle, UK) and classified them with a four-tiered
scoring system: 0, +1, +2, and +3. For cases with IHC
scores of +2 or +3, fluorescence in situ hybridization
(FISH) was used to detect ALK translocation by previ-
ously reported methods [22,23]. Concordance between
IHC and FISH is high; thus, it is appropriate to use the
sensitive IHC method for screening and FISH as a stand-
ard diagnostic test to detect ALK rearrangements [24].
Table 1 Pathologic classification of GGO nodules
according to the IASLC/ATS/ERS criteria, 2011
Number ALK positive EGFR positive
Total 217 6 119





Lepidic predominant 36 1 19
Acinar predominant 93 3 53










Enteric 1 0 0
Adenosquamous carcinoma 1 0 1
Table 2 Clinicopathological characteristics according to
ALK rearrangement status
ALK positive ALK negative P value
N 6 211
Age 60.00 ± 12.05 63.22 ± 10.13 0.579
Sex (M:F) 2:4 96:115 0.692
PYR 0.750 ± 1.173 9.769 ± 17.381 0.464








Nodal involvement 2 13 0.060




Maximal diameter 33.583 ± 13.736 22.528 ± 10.690 0.037
Solid diameter 23.217 ± 16.906 11.452 ± 10.920 0.039
TDR 0.533 ± 0.327 0.700 ± 0.290 0.209
*Data for pathologic stage were unavailable for 5 patients.
†Data for histologic invasiveness were unavailable for 1 patient.
Ko et al. BMC Cancer 2014, 14:312 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/312Statistical analysis
Statistical analysis was performed in SPSS version 18.0
for Windows (SPSS Inc., Chicago, IL). Numerical vari-
ables are expressed as mean ± standard deviation. All
statistical tests were two-sided, and differences were
considered statistically significant at P < 0.05.
Results
Patient characteristics
We recruited 289 patients who underwent surgical treat-
ment for nGGOs from August 2009 to March 2013 at
SNUBH. After pathologic confirmation of the surgical
specimens, nine patients were excluded with diagnoses
of non-cancerous lung conditions, including three inter-
stitial fibroses, two lymphoplasma cell infiltrations, two
chronic inflammations, one anthracofibrotic nodule, and
one AAH. The remaining 280 nGGOs in 261 patients
were considered lung cancer, including adenocarcinoma,
squamous cell carcinoma, and adenosquamous carcin-
oma. We excluded 63 nGGOs in 46 patients for whom
EGFR and/or ALK status was unavailable. Finally, 217
nGGO lesions in 215 patients were enrolled. Two pa-
tients had multiple nGGO lesions, which were tested for
biomarker status. All nodules were diagnosed as adeno-
carcinoma, except one, which was identified as adenos-
quamous carcinoma.
Pathologic classification of GGO nodules
Pathologic findings of 217 nGGOs were classified according
to the 2011 IASLC/ATS/ERS classification. Numbers of
AIS, MIA, and IA were 15, 16, and 185, respectively, and
there was one adenosquamous carcinoma. Acinar predom-
inant adenocarcinoma was the most frequent type in
nGGOs. Seven solid predominant adenocarcinomas and
five invasive mucinous adenocarcinomas also presented as
nodules with GGOs. Six ALK rearrangement-positive
(ALK-positive) nGGOs were invasive adenocarcinomas,
whereas 11.8% (14 out of 119) of EGFR mutation-positive
nGGOs were pre-invasive or minimally invasive adenocar-
cinomas. Subtypes of invasive adenocarcinoma revealed no
statistical difference between ALK rearrangement and
EGFR mutation-positive nGGOs (Table 1).
Analysis of ALK- and EGFR mutation-positive nodules
FISH identified ALK rearrangements in six lesions
(2.8%) and EGFR mutations in 119 lesions (54.8%).
These driver gene mutations were mutually exclusive in
the examined nGGOs.
ALK-positive GGO nodules
Histopathology revealed that patients with ALK-positive
nGGOs exhibited more advanced disease stages according
to the AJCC, 7th edition (p = 0.018) (Table 2). ALK-posi-
tive nodules were significantly larger than ALK-negative
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nodules was also significantly larger than that of ALK-
negative nodules (p = 0.039). All ALK-positive nodules
were IA according to the 2011 IASLC/ATS/ERS classifica-
tion; three nGGOs were acinar predominant subtypes,
one was the solid subtype, one was the lepidic subtype,
and one was the papillary predominant subtype (Table 1).
Three nodules showed cribriform features and one nodule
showed a signet ring cell pattern.
EGFR mutation-positive GGO nodules
EGFR mutations were more frequent in women (p =
0.004) and in non-smokers or light smokers (p < 0.001).
nGGOs with EGFR mutations did not significantly non-
mutated lesions in terms of nodule size, solid proportion,
nodal involvement, pathologic stage, and histologic inva-
siveness (Table 3). Among nGGO lesions with EGFR mu-
tations, 56 nodules had a point mutation in exon 21
(L858R mutation in 54, L861Q in 1, and G863C in 1). Pa-
tients with EGFR mutations in exon 21 were older than
patients with wild-type EGFR lesions (p = 0.034), were
more likely to be non-smokers or light smokers (p =
0.002), and were more frequently women (p = 0.001). Pa-
tients with EGFR mutations in exons 19 or 20 showed noTable 3 Clinicopathological characteristics according to
EGFR mutation status
EGFR positive EGFR negative P value
N 119 98
Age 63.50 ± 9.11 62.68 ± 11.35 0.559
Sex (M:F) 43:76 55:43 0.003
PYR 5.805 ± 14.426 14.031 ± 19.193 <0.001








Nodal involvement 5 10 0.106




Maximal diameter 22.387 ± 9.876 22.376 ± 12.052 0.507
Solid diameter 11.133 ± 11.229 12.559 ± 11.257 0.353
TDR 0.702 ± 0.295 0.687 ± 0.290 0.720
*Data for pathologic stage were unavailable for 2 EGFR positive and 3 EGFR
negative patients.
†Data for histologic invasiveness were unavailable for 1 patient.significant clinicopathological and radiologic differences in
comparison to those without EGFR mutations (Table 4).
Comparison between groups with distinct molecular
biomarkers
No significant demographic differences were found be-
tween the two molecular biomarker groups. Interestingly,
nGGOs with ALK rearrangement were associated with
significantly higher pathologic stage and larger maximal
and solid diameter in comparison to nGGO lesions with
EGFR mutation, but not in TDR. All ALK-positive nodules
were classified as IA, but this trend was not significant
due to the relatively small sample size (Table 5).
Comparison of EGFR mutation and ALK rearrangement rate
in GGO nodules to previous studies of a large cohort of
adenocarcinomas
The prevalence of EGFR and ALK mutations in GGO
nodules in this study was compared to previous reports
of adenocarcinoma of all types. As summarized in
Table 6 the ALK rearrangement rate (2.8%) in this study
was quite low. We previously reported an ALK re-
arrangement rate of 6.8% in all types of adenocarcinoma
[23]. Other reports from Korean institutes showed
higher rates of ALK rearrangement [5.4% [25] and 20.4%
[26]]; however, no significant difference was found in
EGFR mutation rate.
Discussion
Lung cancer, in its early stage, can present as nGGOs on
chest CT. Lung adenocarcinoma with growth patterns
involving the alveolar septum and a relative lack of aci-
nar filling shows GGOs on chest CT, and a high GGO
proportion is correlated with good prognosis [27]. Path-
ology of GGO nodules has shown that the proportion of
GGO in nodular adenocarcinomas decreases through
the AAH-AIS-MIA-IA pattern of progression [28], and
that GGO nodules must undergo in situ changes, since
AIS (formerly called BAC) and precancerous lesions
such as AAH correspond to pure GGO [15].
The clinicopathologic, radiologic, and molecular bio-
logical characteristics of nGGOs are important for our
understanding of the mechanism of carcinogenesis and
for predicting the chemotherapeutic response. Since the
introduction of molecular targeting agents, many groups
have studied the EGFR mutation status of nGGOs, but
there is little data on ALK rearrangements in nGGOs.
EGFR mutations are frequently found in the early stages
of nGGO, such as in AAH and AIS, and play an import-
ant role in the pathogenesis of adenocarcinoma with
GGO patterns. However, the role of ALK rearrangement,
another potent driver mutation in adenocarcinoma, has
not been described in GGO nodules.
Table 4 Clinicopathological characteristics according to EGFR mutation type
EGFR exon 19 EGFR exon 20 EGFR exon 21 EGFR negative
N 50 9 56 (L858R in 54) 98
Age 60.40 ± 8.83 64.22 ± 8.04 66.45 ± 8.80** 62.68 ± 11.35
Sex M:F = 23:27 M:F = 4:5 M:F = 16:40** 55:43
PYR 8.09 ± 14.90 2.72 ± 6.55 4.68 ± 15.25** 14.03 ± 19.19
Pathologic stage 50 9 54* 95
0 4 0 2 9
IA 40 6 38 57
IB 4 2 12 18
IIA 0 0 1 5
IIB 1 1 0 0
IIIA 1 0 1 5
IIIB 0 0 0 1
Nodal involvement 1 1 2 10
Histologic invasiveness 50 9 55† 98
AIS 4 0 2 9
MIA 7 0 4 5
IA 39 9 49 84
Maximal diameter 21.294 ± 10.713 26.944 ± 12.692 22.950 ± 8.769 22.376 ± 12.052
Solid diameter 9.392 ± 11.754 16.489 ± 15.322 11.900 ± 10.303 12.559 ± 11.257
TDR 0.765 ± 0.283 0.592 ± 0.312 0.679 ± 0.296 0.692 ± 0.292
*Data for pathologic stage were unavailable for 2 patients.
†Data for histologic invasiveness were unavailable for 1 patient.
**P value < 0.05 compared with EGFR-negative patients.
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copathological characteristics of driver mutations, focus-
ing on ALK rearrangement in resected adenocarcinoma
with GGO patterns. To our knowledge, this is the largest
comprehensive analysis of lung cancer presenting as
GGO nodules. We included lung cancer nodules exhibit-
ing any amount of GGO regardless of its size, thereby
investigating the molecular biomarker status of lung
cancer at early stages.
Adenocarcinoma with ALK rearrangement is usually
found in younger, female patients who have light to no
smoking history, and has been reported to have acinar,
papillary, cribriform, and signet-ring patterns. The radio-
logical characteristics of lung cancer with ALK re-
arrangement have hardly been studied, and there is a
lack of data concerning the role of ALK rearrangement
in nGGO lesions. In one study, Fukui et al. reported that
no GGO nodules were found in patients with ALK re-
arrangement while 50% of adenocarcinomas that did not
have ALK rearrangement also had GGO nodules and
also EML4-ALK-positive tumors mainly exhibited a solid
pattern on CT [29].
In this study, the proportion of ALK-positive nGGO
lesions was significantly lower (2.8%) than that obtained
in previous studies of a large cohort of adenocarcinomas(3.9-20.4%) (Table 6) [23,25,26,29-32], and was signifi-
cantly lower than the 6.8% of 395 resected adenocarcin-
oma patients in our previous study, which included all
types of curatively resected adenocarcinoma [23]. This
could be indirect evidence of the lower incidence of
ALK rearrangements in adenocarcinomas with GGO
patterns compared to adenocarcinomas of all types.
It is well known that ALK-positive adenocarcinoma is
likely to present a signet-ring cell or cribriform pattern
and abundant mucin production on histological analysis
[33,34]: ALK-positive lesions are observed as a solid, ra-
ther than a GGO, nodule [29,35,36]. This explains the
low proportion of ALK-positive patients in this study,
which focuses on nGGOs. Fukui et al. studied the radio-
logic characteristics of 28 ALK-positive adenocarcinomas
and revealed no GGO portion [29] and another report
on CT characteristics of ALK rearranged advanced
NSCLC from Japan also report low frequency of ALK re-
arrangement (one among 36 cases) [36], consistent with
our findings.
We revealed that maximal diameters and the solid
portion of nGGOs with ALK rearrangement were signifi-
cantly larger than were those without ALK rearrange-
ment. All nGGOs with ALK rearrangement were IA
(invasive adenocarcinoma) with acinar predominant
Table 6 Prevalence of biomarker mutations in previous large
Molecular biomarker Author (reference) Frequency
ALK Paik et al. [23] 6.8%
Choi et al. [25] 5.4%
Koh et al. [26] 20.4%
Takeuchi et al. [31] 3.9%
Fukui et al. [29] 3.9%
Wang et al. [32] 8.6%
Rodig et al. [30] 5.6%
This study 2.8%
EGFR Choi et al. [25] 47.1%
Kim et al. [46] 43.5%
Sun et al. [49] 53.1%
Kosaka et al. [47] 49.1%
Uramoto et al. [50] 37.8%
Huang et al. [45] 38.1%
Liam et al. [48] 39.5%
This study 54.8%
Table 5 Clinicopathological characteristics according to
molecular biomarkers in nGGO
EGFR ALK P value*
N 119 6
Age 63.50 ± 9.11 60.00 ± 12.05 0.571
Sex M:F = 43:76 M:F = 2:4 0.889
PYR 5.805 ± 14.426 0.750 ± 1.173 0.942








Nodal involvement 5 2 0.003




Maximal diameter 22.387 ± 9.876 33.583 ± 13.736 0.032
Solid diameter 11.133 ± 11.229 23.217 ± 16.906 0.032
TDR 0.702 ± 0.295 0.533 ± 0.327 0.225
*P value: EGFR vs. ALK.
†Data for pathologic stage were unavailable for 2 patients.
**Data for histologic invasiveness were unavailable for 1 patient.
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tients with ALK-positive lesions showed more advanced
pathologic stages than those with EGFR-positive GGOs.
Therefore, we suggest ALK rearrangement is associated
with cellular and histological type as well as clinical
aggressiveness.
Several studies have revealed that adenocarcinomas
with ALK rearrangement have more lymph node metas-
tases [23,25]. Combined with the radiological character-
istics discussed above, the ALK-positive adenocarcinoma
seems not to follow the stepwise carcinogenesis pattern
of AAH-AIS-MIA-IA, but to grow rapidly and bypass
the phase of lepidic growth. This assumption is consist-
ent with the histological analysis of ALK-positive adeno-
carcinomas showing lower frequencies of lepidic growth
and AAH/BAC (AIS) in the background of ALK-positive
lung adenocarcinomas [35].
Distinct subsets of adenocarcinoma with morphologic
differentiation to type II pneumocytes, Clara cells, or
non-ciliated bronchioles are thought to originate from
the terminal respiratory unit (TRU), and EGFR mutation
is involved with early-stage carcinogenesis of TRU-type
adenocarcinoma [5,37]; nGGOs appear to be another
marker of TRU-type adenocarcinoma [5].
Thyroid transcription factor-1 (TTF-1) is a marker of
TRU-type adenocarcinoma [37,38], and two studies con-
cerning 11 and 12 ALK-positive patients each revealed
TTF-1 positivity in all ALK-positive adenocarcinomas
[26,39]. This finding suggests that this subtype of adeno-
carcinoma may have TRU-origin histogenesis [39]. How-
ever, the low proportion of GGO with ALK rearrangement
and the advanced stage in ALK-positive nGGOs found inpopulation studies of lung adenocarcinoma
Total number Population Remarks
395 Korean Surgically resected
331 Korean Underwent FDG-PET
221 Korean Advanced disease
1121 Japanese Surgically resected
720 Japanese Surgically resected
151 Chinese Advanced disease
358 American Surgically resected, partially
217 Korean nGGO only
331 Korean Underwent FDG-PET
200 Korean -
358 Korean -
224 Japanese Surgically resected
437 Japanese Surgically resected
858 Chinese -
812 Malaysian -
217 Korean nGGO only
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may not follow a process of TRU origin. Further patho-
logic analysis of morphological characteristics is required.
Because the prevalence of adenocarcinoma with ALK
rearrangement is low compared to EGFR mutation, stud-
ies investigating various characteristics of ALK-positive
lung cancer do not gather enough participants to yield
consistent results. Previous studies on a large, unselected
population of adenocarcinoma with ALK rearrangement
reported that patients with ALK-positive lung cancer
were younger [23,29,30,32], female [23,25,40], and light
or non-smokers [23,25,29,30,32,40,41]. We previously
reported that ALK-rearranged lung adenocarcinomas of
all radiologic types showed higher stage at diagnosis and
more solid pattern, were more cribriform, and had a
closer relationship with adjacent bronchioles [42] and
more frequently positive bronchoscopic findings than
EGFR-positive lung adenocarcinoma [43], which sug-
gested more proximal origin of ALK rearranged lung
adenocarcinoma than EGFR-positive adenocarcinoma.
These findings were consistent with low frequency of
ALK rearrangement in nGGOs which presented in per-
ipheral location.
We found no correlation between age, sex, smoking
status, and ALK positivity, probably due to the small
number of ALK-positive patients and the weak represen-
tation of adenocarcinoma, since we enrolled only pa-
tients with nGGOs.
We found that EGFR mutation was associated with fe-
male, never/light smokers, as expected [44]. The fre-
quency of EGFR mutation in nGGOs in this study was
54.8%, which was relatively high in comparison to other,
large cohorts of adenocarcinoma [25,45-50] (Table 6).
However, we could not predict EGFR mutation status by
the GGO proportion of nodules or tumor size. EGFR
mutation status was not associated with pathologic
stage, nodal involvement, or histologic invasiveness.
It is interesting that after stratifying EGFR mutations
in exons 19, 20, and 21, only the mutation in exon 21
(mostly L858R) correlated with female gender and
never/light smoking status. This result is consistent with
other studies of the characteristics of adenocarcinoma
and EGFR mutation type [51,52]. The association be-
tween EGFR and female non- or light smoker may be
limited to EGFR mutation in exon 21.
According to large cohort studies, EGFR mutations and
ALK rearrangements are mutually exclusive. However,
several cases of co-incident EGFR mutation and ALK
rearrangement have been reported, most of which demon-
strated good response to EGFR tyrosine kinase inhibitors
[32]. In our study, which recruited participants at the early
stage of adenocarcinoma, these molecular biomarkers
were mutually exclusive. It is thought that they act
through different mechanisms in early carcinogenesis.The major strength of study is that it is the largest co-
hort concerning lung cancer with nGGOs. All nodules
were resected by curative surgery, which reinforced the
accuracy of pathologic and molecular diagnoses of the
surgical specimens. Although we collected enough GGO
nodules with EGFR mutations in exons 19 and 21, we
could not collect sufficient numbers of samples with
ALK rearrangement due to the inherent limitation that
adenocarcinoma with ALK rearrangement tends to
present as solid nodules in chest CT.
Conclusions
ALK rearrangement is rare in lung adenocarcinoma pre-
senting as nGGOs and is associated with a more ad-
vanced stage and larger tumor size, suggesting a distinct
origin and an aggressive nature in the progression of
lung adenocarcinoma. ALK rearrangement may not play
an important role in the early pathogenesis of nGGO. It
is important to understand the clinicopathological char-
acteristics of nGGOs associated with each driver muta-
tion, as well as their radiologic correlations, when
individualizing lung cancer treatments with molecular-
targeted therapies.
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